Navitoclax (ABT-263)

For research use only. Not for use in humans.

目录号：S1001

CAS No. 923564-51-6

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 3285.53	现货
5mg	RMB 975.71	现货
10mg	RMB 1631.61	现货
25mg	RMB 3016.58	现货
100mg	RMB 7950.36	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Navitoclax (ABT-263)发表文献252篇：

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Metab, 2019, 30(1):129-142

PubMed: 31155496 ( click the link to review the publication )

Cancer Discov, 2018, 8(12):1598-1613

PubMed: 30254092 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(2):112-117

PubMed: 29200207 ( click the link to review the publication )

Cancer Cell, 2017, 32(4):490-505.e10

PubMed: 29017059 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Dev Cell, 2021, S1534-5807(21)00360-9

PubMed: 34004159 ( click the link to review the publication )

Cell Rep, 2021, 34(11):108870

PubMed: 33730585 ( click the link to review the publication )

Cell Rep, 2021, 36(1):109334

PubMed: 34233184 ( click the link to review the publication )

Haematologica, 2021, 10.3324/haematol.2021.278743

PubMed: 34162179 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-021-01910-6

PubMed: 34193942 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):406

PubMed: 33859162 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):54

PubMed: 33423045 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):121

PubMed: 33495462 ( click the link to review the publication )

Br J Cancer, 2021, 10.1038/s41416-021-01441-7

PubMed: 34088988 ( click the link to review the publication )

Mol Cancer Res, 2021, 19(4):651-666

PubMed: 33443106 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(2)E752

PubMed: 33451095 ( click the link to review the publication )
Int J Mol Sci, 2021, 22(8)3811

PubMed: 33917026 ( click the link to review the publication )

Sci China Life Sci, 2021, 10.1007/s11427-021-1933-7

PubMed: 34109475 ( click the link to review the publication )

Transl Oncol, 2021, 14(5):101048

PubMed: 33667892 ( click the link to review the publication )

BMC Complement Med Ther, 2021, 21(1):88

PubMed: 33750370 ( click the link to review the publication )

PLoS Comput Biol, 2021, 17(2):e1008630

PubMed: 33617523 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):121

PubMed: 33495462 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1134

PubMed: 33602934 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1281

PubMed: 33627663 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):60

PubMed: 34040000 ( click the link to review the publication )

Nat Cell Biol, 2020, 4

PubMed: 32367049 ( click the link to review the publication )

Sci Transl Med, 2020, 15;12(539) pii: eaax3799

PubMed: 32295900 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

Nat Commun, 2020, 11(1):752

PubMed: 32029722 ( click the link to review the publication )

Nat Commun, 2020, 11(1):259

PubMed: 31937780 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Blood Cancer J, 2020, 10(6):72

PubMed: 32591499 ( click the link to review the publication )

Aging Cell, 2020, 19(4):e13133

PubMed: 32175667 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33393

PubMed: 33186476 ( click the link to review the publication )

Eur J Cancer, 2020, 126:93-103

PubMed: 31927215 ( click the link to review the publication )

J Med Chem, 2020, 63(22):13733-13744

PubMed: 33197310 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2551

PubMed: 32911681 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(2) pii: E406

PubMed: 32050632 ( click the link to review the publication )
Breast Cancer Res, 2020, 22(1):130

PubMed: 33239070 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):854

PubMed: 33056980 ( click the link to review the publication )

Cell Death Dis, 2020, 8;11(6):443

PubMed: 32513939 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(11)E1143

PubMed: 33218059 ( click the link to review the publication )

Mol Cancer Res, 2020, molcanres.0586.2020

PubMed: 33288732 ( click the link to review the publication )

PLoS Negl Trop Dis, 2020, 14(3):e0008150

PubMed: 32196500 ( click the link to review the publication )

Sci Rep, 2020, 14;10(1):222

PubMed: 31937836 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 4;526(3):612-617

PubMed: 32247610 ( click the link to review the publication )

Laryngoscope, 2020, 10.1002

PubMed: 31894587 ( click the link to review the publication )

Platelets, 2020, 10.1080/09537104.2020.1724276

PubMed: 32079453 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Biomater Sci, 2020, 8(8):2264-2273

PubMed: 32134074 ( click the link to review the publication )

Cancer Lett, 2020, S0304-3835(20)30635-2

PubMed: 33259900 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2020, S0360-3016(20)34731-3

PubMed: 33385497 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0234103

PubMed: 32645016 ( click the link to review the publication )

Leuk Lymphoma, 2020, 1-5

PubMed: 32627634 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):537-548

PubMed: 31911540 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(14):14174-14188

PubMed: 32692721 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):95

PubMed: 32677976 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2137

PubMed: 32752193 ( click the link to review the publication )

Cancers (Basel), 2020, 12(8):E2298

PubMed: 32824203 ( click the link to review the publication )
Int J Radiat Oncol Biol Phys, 2020, 15;106(4):867-877

PubMed: 31786278 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Trop Life Sci Res, 2020, 31(3):1-13

PubMed: 33214852 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107830

PubMed: 32610131 ( click the link to review the publication )

Free Radic Biol Med, 2020, 152:227-234

PubMed: 32217194 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.201900218R

PubMed: 32619061 ( click the link to review the publication )

Mol Cell, 2019, 74(1):19-31

PubMed: 30878284 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Sci Adv, 2019, 5(7):eaau9433

PubMed: 31392262 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0775

PubMed: 31806643 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30860026 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

J Med Chem, 2019, 62(15):6913-6924

PubMed: 31339316 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

FASEB J, 2019, 10.1096/fj.201900815RR

PubMed: 31408372 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(23)

PubMed: 31801186 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

J Biol Chem, 2019, 294(3):875-886

PubMed: 30482844 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:218

PubMed: 31462891 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:222

PubMed: 31467488 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Cell Biosci, 2019, 9:60

PubMed: 31367332 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Photodiagnosis Photodyn Ther, 2019, 10.1016/j.pdpdt.2019.08.016

PubMed: 31430575 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Nat Metab, 2019, 1(11):1074-1088

PubMed: 31799499 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Immunity, 2018, 48(4):675-687

PubMed: 29653696 ( click the link to review the publication )

J Allergy Clin Immunol, 2018, 142(5):1647-1650.e3

PubMed: 30048671 ( click the link to review the publication )

Nat Commun, 2018, 9(1):215

PubMed: 29335437 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Neuro Oncol, 2018, 20(2):203-214

PubMed: 29016820 ( click the link to review the publication )

Oncogene, 2018, 37(22):2936-2952

PubMed: 29520102 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )
Cell Death Dis, 2018, 9(7):713

PubMed: 29915306 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 48(3):1123-1138

PubMed: 30041196 ( click the link to review the publication )

Mol Oncol, 2018, 12(3):287-304

PubMed: 29063678 ( click the link to review the publication )

Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Sci Rep, 2018, 8(1):16822

PubMed: 30429524 ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Cell Cycle, 2018, 17(17):2175-2186

PubMed: 30198376 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Oncotarget, 2018, 9(28):20075-20088

PubMed: 29732004 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16701-16717

PubMed: 29682179 ( click the link to review the publication )

J Exp Med, 2018, 215(1):319-336

PubMed: 29263218 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1226-1236

PubMed: 28945232 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1116-1129

PubMed: 28846096 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):635-650

PubMed: 28094768 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1940

PubMed: 29208897 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )
Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

J Cell Biol, 2017, 216(11):3655-3675

PubMed: 28877995 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2512-2521

PubMed: 28202514 ( click the link to review the publication )

Aging Cell, 2017, 16(4):693-703

PubMed: 28401730 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2563-2571

PubMed: 28839001 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Cell Discov, 2017, 3:16048

PubMed: 28101374 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Tumour Biol, 2017, 39(5):1010428317699120

PubMed: 28459212 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Nat Microbiol, 2016, 1:15034

PubMed: 27572165 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Autophagy, 2016, 12(7):1083-93

PubMed: 27172402 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )
Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(6):1624-9

PubMed: 26811457 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Int J Cancer, 2016, 138(2):507-14

PubMed: 26260669 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Aging (Albany NY), 2016, 8(11):2915-2926

PubMed: 27913811 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Cell Cycle, 2016, 15(3):394-402

PubMed: 26694174 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164250

PubMed: 27723829 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )

J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Oncotarget, 2016, 7(50):82013-82027

PubMed: 27852038 ( click the link to review the publication )

Oncotarget, 2016, 7(1):845-59

PubMed: 26625317 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34453-71

PubMed: 27144341 ( click the link to review the publication )

EMBO Rep, 2015, 16(5):618-27

PubMed: 25739811 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2959-70

PubMed: 26096065 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )
Cell Death Dis, 2015, 6:e2034

PubMed: 26720343 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Sci Rep, 2015, 5:14739

PubMed: 26446703 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

PLoS One, 2015, 10(1):e0116998

PubMed: 25615615 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

Oncol Lett, 2015, 10(2):829-834

PubMed: 26622578 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Oncotarget, 2015, 6(29):27388-402

PubMed: 26317541 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21557-71

PubMed: 26188358 ( click the link to review the publication )

Oncotarget, 2015, 6(17):15551-65

PubMed: 26036632 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26059440 ( click the link to review the publication )

Oncotarget, 2015, 6(34):36456-71

PubMed: 26474387 ( click the link to review the publication )

Sci Rep, 2015, 5:16406

PubMed: 26553339 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1028

PubMed: 24481442 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )

PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10237-50

PubMed: 25296978 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Haematologica, 2013,

PubMed: 23850807 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

J Neurosci, 2013, 33(12):5195-207

PubMed: 23516285 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

PLoS One, 2013, 8(5):e64051

PubMed: 23691145 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 434(3):695-700

PubMed: 23602897 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )
Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(12):3956-68

PubMed: 21652541 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4518-26

PubMed: 21546570 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述

Navitoclax (ABT-263)是一种有效的Bcl-xL，Bcl-2和Bcl-w抑制剂，无细胞试验中K_i分别为≤0.5 nM，≤1 nM和≤1 nM，但与Mcl-1和A1结合微弱。Phase 2。

靶点

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

体外研究

ABT-263有效抑制Bcl-2蛋白家族，用荧光偏振分析法测试ABT-263作用于Bcl-xL, Bcl-2和 Bcl-w时，K_i分别为0.5, 1和1 nM。^[1]ABT-263结构上与ABT-737相关。ABT-263阻断Bcl-2 和Bcl-XL与凋亡前体蛋白相互作用。Bcl-2家族成员Bcl-2,Bcl-XL, 和Mcl-1的过量表达通常都与肿瘤的修复及抗药性有关。ABT-263作用于过量表达的Bcl-2 和Bcl-XL时显示出保护作用，EC50分别为60 和20 nM。ABT-263作用于不同的细胞显示出不同的细胞活性，作用于H146细胞系时EC50为110nM,而作用于H82细胞系时EC50为22 µM。ABT-737可以有效作用于四种EC50值 <400 nM的细胞系，即H146, H889, H1963, 和H1417。而两种抗ABT-737的细胞系，即H1048和H82，同样也显示出抗ABT-263的特性。^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
FL5.12	NYfWdW5jS3m2b4TvfIlkcXS7IHHzd4F6	M1jPbFI1KGh?	NWPyWoh5TUN3MDC9JFAvODB2MjFOwG0>	M3z5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OESxPFgzLz5zOEi0NVg5OjxxYU6=
FL5.12	M{jvTWN6fG:2b4jpZ4l1gSCjc4PhfS=>	MX6yOEBp	M{XYb2VEPTBiPTCwMlAxPTlizszN	MmDkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6NEG4PFIoRjF6OESxPFgzRC:jPh?=
RS4:11	M4XISWFxd3C2b4Ppd{Bie3OjeR?=	M2jPdFYhcA>?	MkXPSWM2OCB;IECuNFE1KM7:TR?=	NVrNUXE5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2PjdpPkK0PFgyPTZ5PD;hQi=>
FDC-P1	MoezRmNNNTJiaX7obYJqfGmxbjDhd5NigQ>?	MmfLNlQhcA>?	MVXJR\|UxKD1iMD6wNVUh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6MUW2O{c,OjR6OEG1Olc9N2F-
NCI-H1963	MnvBR5l1d3SxeHnjbZR6KGG\|c3H5	MY[0JIRigXN?	MlXTTWM2OCB;IECuNFI3PiEQvF2=	MnWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2NEiyPVgoRjJ\|NES4Nlk5RC:jPh?=
NCI-H187	NVnzdIQ5S3m2b4TvfIlkcXS7IHHzd4F6	M3fPZ\|Qh\GG7cx?=	NGXkOlVKSzVyIE2gNE4xOzh2IN88US=>	NIfxTYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S0PFI6QCd-MkO0OFgzQTh:L3G+
NCI-H1417	MlzGR5l1d3SxeHnjbZR6KGG\|c3H5	NX\3R2huPCCmYYnz	Mo\HTWM2OCB;IECuNFU1OiEQvF2=	NYfFfncyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0OFgzQThpPkKzOFQ5Ojl6PD;hQi=>
FDC-P1	NYrQT2JySkOOLYjMJIlvcGmkaYTpc44h[XO\|YYm=	NF\hRXAzPCCq	Ml\CTWM2OCB;IECuNFYh\|ryP	NV3W[3d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2PjdpPkK0PFgyPTZ5PD;hQi=>
NCI-H146	MojGR5l1d3SxeHnjbZR6KGG\|c3H5	NHLPUWs1QCCq	NHjKPZFGSzVyIE2gNE4xQDZ5IN88US=>	NYTkNGc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4OFE5QDJpPkG4PFQyQDh{PD;hQi=>
RS4:11	NEfONYpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NXTjUJhOTUN3MDC9JFAvOTF{IN88US=>	M4jPflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUK2NlQ4Lz5{OEmyOlI1PzxxYU6=
MOLT4	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M3;VOmVEPTBiPTCwMlMxOyEQvF2=	MorBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7Mk[yOFcoRjJ6OUK2NlQ4RC:jPh?=
EoL-1-cell	NE\GO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXPJR\|UxRTBwMEC2Olkh\|ryP	MnyxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MV-4-11	M1HIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEnDT3VKSzVyPUCuNFE2QDZizszN	M4KxXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NKM-1	M{LqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NU\4XoJEUUN3ME2wMlAyPjl7IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ML-2	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFT4ZZFKSzVyPUCuNFE6QDNizszN	NWq1SIY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BV-173	M2nFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn3GTWM2OD1yLkCyN\|E1KM7:TR?=	MlLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RS4-11	NXrpTYkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXTnbHJHUUN3ME2wMlAzPTh5IN88US=>	NHjyXGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HL-60	NIjYfWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MU\JR\|UxRTBwMEK5NFgh\|ryP	Mo\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KY821	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M37xdWlEPTB;MD6wNlk4PSEQvF2=	MknLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ECC10	NYDZWFd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M37uTWlEPTB;MD6wN\|c6OiEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H720	NWfNRnZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWfQNlgyUUN3ME2wMlA1ODFzIN88US=>	Mlj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	NFP0OlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVrJR\|UxRTBwMESyPFch\|ryP	NEHHcnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KG-1	NGLIVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXfqfVlbUUN3ME2wMlA1PDh4IN88US=>	M2Hqd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TGW	NFviVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHHDeZBKSzVyPUCuNFQ3OzNizszN	MkLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ATN-1	M{\VPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkX0TWM2OD1yLkC0O\|M{KM7:TR?=	M2D4clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RH-18	MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2j1UGlEPTB;MD6wOlA1QCEQvF2=	MnXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EW-18	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXP2c3JQUUN3ME2wMlA3QDRzIN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NB17	MnLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVrzSHdQUUN3ME2wMlA4OTJ2IN88US=>	NYHxXmJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SK-NEP-1	M332TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHWwWFhKSzVyPUCuNFczOTNizszN	NIfRR2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
P12-ICHIKAWA	M{fWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWTtXHNuUUN3ME2wMlA4Pzd6IN88US=>	NEm0eWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KARPAS-45	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\L[npEUUN3ME2wMlA4QDF3IN88US=>	NEXiOlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EW-3	NITwZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWjJR\|UxRTBwMEiwOVMh\|ryP	M1LxdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB13	NFS0SJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYHJR\|UxRTBwMEiyNFMh\|ryP	NVO4XGkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H209	NXj0ZZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmrUTWM2OD1yLkC4O\|A1KM7:TR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1092	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUPlXI1OUUN3ME2wMlExOjd3IN88US=>	MlzuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NH-12	NUi3[4lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV3JR\|UxRTBwMUC3OFQh\|ryP	M2nCU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
697	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIXSTWlKSzVyPUCuNVA5OzlizszN	NU\SWYVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KE-37	NIn6OYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX;HPWZjUUN3ME2wMlEyOzdizszN	M{TVT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MOLT-4	NFrD[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUnJR\|UxRTBwMUWxOlkh\|ryP	NYHrc3M5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CHP-134	NVGydGZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYfJR\|UxRTBwMU[zNFYh\|ryP	NU\2bIJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
D-283MED	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFrEeZFKSzVyPUCuNVc3QDZizszN	Mle5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LU-135	MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1XTfWlEPTB;MD6xPFU2OiEQvF2=	NVKyOWpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LU-134-A	NYTKNphUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVnJZ41pUUN3ME2wMlE5PjdzIN88US=>	MmnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EM-2	NHna[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYf6VGtLUUN3ME2wMlE6QTF6IN88US=>	M3;KUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LU-139	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVXNSYI6UUN3ME2wMlIxPDl6IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ALL-PO	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHhdpRUUUN3ME2wMlIyQTh6IN88US=>	NEPhXIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NB12	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1TqWGlEPTB;MD6yN\|EyPSEQvF2=	M1TSeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KP-N-YN	M1;tOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWG0XIIxUUN3ME2wMlI{PTd\|IN88US=>	NHjoPII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BEN	NFrafHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NI\ZPXJKSzVyPUCuNlM6PjhizszN	NW\mXW02RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC1569	NEW2UFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnPyTWM2OD1yLkK1NVA3KM7:TR?=	NF;hS2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HuO9	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGHqbVBKSzVyPUCuNlY4OTVizszN	NFPBcFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
WM-115	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUm3NXVNUUN3ME2wMlI4PzN6IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CCRF-CEM	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NW\0O4VWUUN3ME2wMlM{PTJ7IN88US=>	NITWUpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
IST-SL1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1npdWlEPTB;MD6zOVM1OyEQvF2=	Mom1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BE-13	M164b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M17lV2lEPTB;MD6zOlQ2QSEQvF2=	M1;4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COR-L88	M3LVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVfJR\|UxRTBwM{[1OEDPxE1?	NEHzRWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DOHH-2	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYK5c5FzUUN3ME2wMlQyODJ\|IN88US=>	Mn[0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
A704	M3vTZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX7JR\|UxRTBwNEK2O{DPxE1?	M{GxPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KNS-81-FD	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mk\CTWM2OD1yLkS0NFE4KM7:TR?=	M4PXbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RPMI-8226	NH\OfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFj6UlhKSzVyPUCuOFU3PTJizszN	NYPHXJZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TGBC24TKB	M3HRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIL3b5lKSzVyPUCuOFU4PzhizszN	NV3CdFNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1304	M1m5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4\DZ2lEPTB;MD60OlE2PyEQvF2=	NECzO\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MOLT-13	NIXDO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3\sfmlEPTB;MD60OlYyOyEQvF2=	M1\N[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
EW-22	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXvJR\|UxRTBwNE[2O\|Eh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MS-1	NVr2Z49HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHK4V5VKSzVyPUCuOFY6OzNizszN	Mnm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RMG-I	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfvWGhKSzVyPUCuOFk1PjRizszN	NGD1fXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGTMUFNKSzVyPUCuOVAxOTlizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H1048	NWj1VZF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3\5WWlEPTB;MD61NFk2OyEQvF2=	MlXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW1417	NHLJeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVHJR\|UxRTBwNUW0N\|gh\|ryP	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
DB	NVvUW4pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHfGO\|FKSzVyPUCuOVcxQCEQvF2=	NV\GTplNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MEG-01	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlL6TWM2OD1yLkW4N\|Ih\|ryP	NF3YNlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EW-13	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NViwd3NUUUN3ME2wMlU5OzRzIN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
LAMA-84	Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkC5TWM2OD1yLkW5NlA4KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkLrTWM2OD1yLk[wPFA5KM7:TR?=	NVXkVVF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MOLT-16	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGW3WVZKSzVyPUCuOlUzPjRizszN	NVm0[Xp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
DU-4475	M2K1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXzBXoQ1UUN3ME2wMlY2PDJ5IN88US=>	NGPTRpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HAL-01	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\yTWM2OD1yLkeyOVQ6KM7:TR?=	Mo\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RD	NYnVd3B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1zDOGlEPTB;MD63OVg6QSEQvF2=	NYiySIxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OAW-28	MkHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{nkNmlEPTB;MD63PFM4KM7:TR?=	Mn\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC38	M1\lXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYnJR\|UxRTBwOECxPUDPxE1?	NU\4bIw3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NMC-G1	NH\JT\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{DUN2lEPTB;MD64NVEzOSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
EW-16	NGjneW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1G2[2lEPTB;MD64NVMzQCEQvF2=	NFH3bFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DU-145	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHW1OHZKSzVyPUCuPFk6OjNizszN	MoTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HPAF-II	NIXpWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mk\XTWM2OD1yLkmyOlI5KM7:TR?=	NV7DTVFMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
A427	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnToTWM2OD1yLkmzNFIzKM7:TR?=	M3PaZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
PA-1	M1WxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXS0cmtYUUN3ME2wMlk2PjR{IN88US=>	MkjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OAW-42	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUfJR\|UxRTBwOU[xOFYh\|ryP	M3LUcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
L-428	NGSweYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHL1S5hKSzVyPUGuNFEzPSEQvF2=	NXq1cFdLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
COLO-824	M3LQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHexXYRKSzVyPUGuNFE4ODhizszN	NI\wUo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
P30-OHK	MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXfPS2dSUUN3ME2xMlA1Pjh6IN88US=>	M1;LV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2170	NGXifpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1fz[2lEPTB;MT6wOlI{KM7:TR?=	NEjzR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HCC2998	NWC0TJVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2jNfGlEPTB;MT6wO\|E{PSEQvF2=	M2Lyb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB14	M3XVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NULxZXFIUUN3ME2xMlE{PzR6IN88US=>	NX3GV3RQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
TGBC1TKB	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkjLTWM2OD1zLkG0NVUzKM7:TR?=	NUPRfppMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KP-N-YS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVLJR\|UxRTFwMU[yN\|Yh\|ryP	NVroflVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CAL-120	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVjJR\|UxRTFwMU[0Nlkh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SBC-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHfuN4ZKSzVyPUGuNVkxPTNizszN	M{XNTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
C32	Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkfmTWM2OD1zLkG5NFg5KM7:TR?=	Mn;YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC2157	MljZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnG5TWM2OD1zLkG5OFk1KM7:TR?=	MkT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-792	NVr4cnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVvLdFJwUUN3ME2xMlIxODdzIN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ES7	M1\td2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFvxXmpKSzVyPUGuNlc6PTFizszN	M{H3O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HEL	NVfvd41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH[3V21KSzVyPUGuN\|ExOjlizszN	MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ES4	NEO2b25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX\JS5dCUUN3ME2xMlM1QTl6IN88US=>	NX3abmlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-SNU-1	NXHWR4pTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3;CW2lEPTB;MT6zOlU2PSEQvF2=	NV\CO3NQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MDA-MB-415	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVXJR\|UxRTFwM{i4OUDPxE1?	M3fCclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2342	NWPieHJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVmzVJFnUUN3ME2xMlQxOjZ7IN88US=>	NF\zNpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NB69	NVG0SpZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLSOodyUUN3ME2xMlQ3OjdzIN88US=>	NVzxZ5JrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
D-247MG	MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NWfQbI14UUN3ME2xMlUyOTJ{IN88US=>	NF3UXWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SCC-4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXfUNVVvUUN3ME2xMlU6QDh5IN88US=>	M2HUOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HuH-7	NWLCXIZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXLJR\|UxRTFwNkeyPVMh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
A388	NUjibYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlvNTWM2OD1zLk[4O\|I1KM7:TR?=	MkXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Calu-3	MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2[ycGlEPTB;MT63NFY6PyEQvF2=	NFGyWmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H1648	NHzEXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkLkTWM2OD1zLkexOFE5KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2052	NH3WR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF;lfpVKSzVyPUGuO\|IzODFizszN	NEjQcIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NILZ[mpKSzVyPUGuO\|M3PTZizszN	MlT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
DEL	M3zyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH:3bFlKSzVyPUGuO\|Q3QTJizszN	NF3TR5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SNU-423	NHuwe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEXNS3hKSzVyPUGuO\|gyPTdizszN	Mn;xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COR-L23	NUjn[VdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{jtbWlEPTB;MT63PVg4PCEQvF2=	M4XYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
OMC-1	MlvvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXrJR\|UxRTFwOE[wNVYh\|ryP	NVy4TVBmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
EW-11	NEn6fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MljrTWM2OD1zLkm1OlU4KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HSC-3	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlLnTWM2OD1zLkm2N\|Y2KM7:TR?=	NHfzUGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MLMA	NUfVUGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4nMXmlEPTB;MT65OlY4PyEQvF2=	MnHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RCM-1	NFftOoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NF:3Zo5KSzVyPUKuNFA{QTlizszN	NIDtRVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MFE-280	M1zSTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGTheYRKSzVyPUKuNFI5PDhizszN	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ES8	NVrWcmxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVzte5I6UUN3ME2yMlI2PDdzIN88US=>	NHPCfHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TE-11	M1TTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGPFUJpKSzVyPUKuNlk1PzNizszN	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HuO-3N1	M{fqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXS1U2xHUUN3ME2yMlQ5PzhizszN	NWrBc2RORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MHH-NB-11	M1zGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXPJR\|UxRTJwNUGxOVgh\|ryP	M4XIWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
TGBC11TKB	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIP2[WZKSzVyPUKuOVc3QDFizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HOP-92	NVW2d20{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEPMXFRKSzVyPUKuOVg4PDNizszN	M3LIW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
IGR-1	NYHLboZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUXJR\|UxRTJwNkKwN\|Uh\|ryP	NIqyZ3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GOTO	NHjZWXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUHJR\|UxRTJwNkWzO\|ch\|ryP	M3PaVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1650	NFXNRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{i5bmlEPTB;Mj63NlIyPSEQvF2=	M{LJd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1581	M37BRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVLTPYNsUUN3ME2yMlc6PjhzIN88US=>	NWnINGdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H2405	M1jHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MY\JR\|UxRTJwOEK3PFIh\|ryP	NGq2[4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
U-118-MG	M4jTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXLJR\|UxRTJwOU[0PVEh\|ryP	Mn\ZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
DoTc2-4510	NGS0WHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEHhUo9KSzVyPUOuNFE1OTdizszN	NXHOdo1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H596	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF3SSplKSzVyPUOuNFQ6QTdizszN	M1nMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MPP-89	NIDhd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXz3XpdFUUN3ME2zMlA2PjZ4IN88US=>	MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
GCIY	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M13HXWlEPTB;Mz6yNFQ6OSEQvF2=	NG\U[Yk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW626	M1\5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX\JR\|UxRTNwMkS1OFMh\|ryP	NUe3R5VnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OCI-AML2	M3z4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGrKSmVKSzVyPUOuN\|EzPzJizszN	M1T0WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NBsusSR	NFrRcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX7SeJczUUN3ME2zMlM1QTN6IN88US=>	NWf1OpA5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
AN3-CA	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml7CTWM2OD1\|LkS0NlM5KM7:TR?=	NIXmcHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EFM-19	Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXHhcVZbUUN3ME2zMlQ5OzN7IN88US=>	MlvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RVH-421	NH;ZSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoS2TWM2OD1\|LkW2PFc4KM7:TR?=	M4T0SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
5637	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkTzTWM2OD1\|Lk[xNVA{KM7:TR?=	NFHEO5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
PANC-08-13	M1jReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVfJR\|UxRTNwNkO0O\|Ih\|ryP	MmnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
H9	NGnYVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIPwbJpKSzVyPUOuOlcyPDRizszN	M4P4fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KARPAS-299	NXrZUmZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NW\OTFdRUUN3ME2zMlY4OzZzIN88US=>	MoryQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TE-5	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NITlVo5KSzVyPUOuO\|A4ODlizszN	M3\ycFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NOS-1	M1iyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYf5PI55UUN3ME2zMlc6QDN2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HH	M1jhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmSyTWM2OD1\|LkizPFY5KM7:TR?=	MmD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
769-P	NEnlRZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1LwVmlEPTB;Mz64PVUyKM7:TR?=	NX3XZ\|RxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CHP-212	NEfyWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnPjTWM2OD1\|LkmyOVQ6KM7:TR?=	NHPYWWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H82	NGnIS\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M331dWlEPTB;Mz65OVk{PiEQvF2=	M1qwSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Mo-T	NGj0[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MonETWM2OD12LkC0N\|EzKM7:TR?=	MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BB65-RCC	NFzWOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml;FTWM2OD12LkC0N\|k6KM7:TR?=	M1zod\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW1990	MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVrPR5c5UUN3ME20MlA2QTB6IN88US=>	MlXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LK-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVzvTVltUUN3ME20MlEyOjl\|IN88US=>	M3TFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ES5	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXzMVohyUUN3ME20MlE{QTh3IN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
JVM-3	M33Demdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF7EUGFKSzVyPUSuNVgzOjJizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
RPMI-7951	NFHYXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVLBfXEzUUN3ME20MlIzPDF\|IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
Calu-6	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYnJR\|UxRTRwMke4PFEh\|ryP	M1jER\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LC-2-ad	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmLuTWM2OD12LkK5OVY5KM7:TR?=	MoTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW954	NXmyUZk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mki0TWM2OD12LkK5OlYh\|ryP	M2m4[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
H-EMC-SS	M2f6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUXJR\|UxRTRwM{G4N\|Eh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
ES3	NYrFOVh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYPQd2RxUUN3ME20MlM2PDRzIN88US=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
no-11	M{XEPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFLJZW9KSzVyPUSuN\|U2PTRizszN	MkXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LAN-6	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGnKNIVKSzVyPUSuOFUyQDlizszN	NIW2S5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
FTC-133	NYKyXHdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEftfGZKSzVyPUSuOVM6PSEQvF2=	M3Tq[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
8505C	MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYfJR\|UxRTRwNUSyN{DPxE1?	M2HZ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW620	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;EemlEPTB;ND61O\|A2PyEQvF2=	M17HdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BCPAP	M{nw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIL2dYVKSzVyPUSuOlM1QDFizszN	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-LU-1	M2HQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFzyZmFKSzVyPUSuOlYxQDlizszN	M4TsfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1623	NXjWVpl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEnrfmZKSzVyPUSuO\|AzOjhizszN	NWrLRXozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
C2BBe1	NX74V4lTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY\JR\|UxRTRwN{SwNFgh\|ryP	M3G2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
GP5d	MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIL6V25KSzVyPUSuO\|g{QDhizszN	M1HyTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NB6	MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHnjNo9KSzVyPUSuPFYzODRizszN	NETFcW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MDA-MB-157	NHzNd\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2K0[2lEPTB;ND64PFc3KM7:TR?=	NVTHSnlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
UMC-11	NFzQTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoPrTWM2OD12Lki4PVY1KM7:TR?=	NXv4fGdjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC1419	M2f4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWnJR\|UxRTRwOUCwOlMh\|ryP	NEW0ToQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2029	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnjqTWM2OD12Lkm0NVg2KM7:TR?=	NELLfXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LXF-289	NYXSVHNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M371WGlEPTB;NT6wN\|cyQSEQvF2=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KINGS-1	NYHLVXRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3KyTGlEPTB;NT6wO\|c1PCEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HD-MY-Z	NUfWO3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NE\kTYJKSzVyPUWuNlM6PjlizszN	M{TMXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
ESS-1	NE\pUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoLaTWM2OD13LkK1OVk4KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
GI-1	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkewTWM2OD13LkK3PVI3KM7:TR?=	Mn7XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
RPMI-2650	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfleHJKSzVyPUWuN\|YyPiEQvF2=	NWXBbotYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
IA-LM	NWjGW\|JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1q2OGlEPTB;NT6zPVg4OSEQvF2=	Mn30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KP-4	NE\EOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M37Eb2lEPTB;NT60OlM{PCEQvF2=	NFvOdXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
G-402	NX3nc5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NG[5WlZKSzVyPUWuOVE5PjVizszN	Ml7NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OS-RC-2	NXvkfYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX[4SnpPUUN3ME21MlUzPjB2IN88US=>	NWnQd3FqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NCI-H1155	M1HYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHPNTmxKSzVyPUWuOVQ6PTVizszN	NXfFcW1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OE19	NUjYUXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2fyemlEPTB;NT62PFYzPCEQvF2=	MmroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
U-2-OS	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn[yTWM2OD13Lki5NFE{KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SCC-15	NULDeVZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoTlTWM2OD13LkmzOlYzKM7:TR?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H630	M{fXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2PYVWlEPTB;NT65PVQxPCEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
PFSK-1	NV7CRXpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{nySmlEPTB;Nj6wOVI2QSEQvF2=	M3vqW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1770	M4fWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXvJR\|UxRTZwMkC4O\|Qh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-3	NYPYdpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXfJR\|UxRTZwNEK5NVUh\|ryP	NGruR5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LB1047-RCC	NXi3dJJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUnJR\|UxRTZwNEe2NlUh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H446	NUWxcoMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXPJR\|UxRTZwNkK5NlUh\|ryP	NUXkeWRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SW780	MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfGeYhKSzVyPU[uO\|AyQDVizszN	NHvZZ4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NEC8	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{Pnc2lEPTB;Nj63OlY{KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NOMO-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXXzZVJ[UUN3ME22Mlc5OTFzIN88US=>	MnP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-668	M4XDWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGHqSHNKSzVyPU[uPFQ{QDdizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MC116	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml\4TWM2OD14LkmzPFk4KM7:TR?=	MmniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC1937	NUTZV3lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmmxTWM2OD14Lkm5NlUyKM7:TR?=	M{P3XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-N87	M3PzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NESy[m1KSzVyPUeuNVkzQTNizszN	MljSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-320-HSR	NH7YUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXLUWng1UUN3ME23MlIzPzN6IN88US=>	NYPhVodkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
HCC1806	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHLFdZJKSzVyPUeuNlYxPDRizszN	NUX4fXFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
OVCAR-3	M4jrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWjJR\|UxRTdwM{OwN\|gh\|ryP	NYjLS5U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NUGC-3	NFG3fFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3\GWGlEPTB;Nz6zPVY6PCEQvF2=	M4jU[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW1783	NESyO\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGXzdZdKSzVyPUeuOFMyPzVizszN	NVnWe2JHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
GCT	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXPJR\|UxRTdwNU[5NFYh\|ryP	NHHSZW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2126	MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfCZZpKSzVyPUeuO\|M3OjVizszN	NY\UO4p[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MEL-HO	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXvkU4VPUUN3ME23Mlc4ODV2IN88US=>	M3jPe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
CAPAN-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWPJR\|UxRTdwN{ezOVch\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW756	M2nkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3:4dWlEPTB;Nz63PFM{OyEQvF2=	Mo\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SKG-IIIa	M2DSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXfJR\|UxRTdwOEG4PVIh\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCE-T	NV:wXmdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF\5O2VKSzVyPUeuPFc4QDNizszN	MoCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Ca-Ski	NGfR[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHPPZ\|FKSzVyPUeuPVk{QDNizszN	M1vXTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-684	Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NELoN3pKSzVyPUiuNFE5OThizszN	M2XneVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-70	M2PnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV;6S\|Y6UUN3ME24MlA4PzJ7IN88US=>	MnP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
TI-73	NFS3WHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIeyeo5KSzVyPUiuNlU5PTFizszN	Mn;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BT-20	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\aTWM2OD16LkK2NFUzKM7:TR?=	NWK0d41sRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
MHH-ES-1	NGDieJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUDFUHRjUUN3ME24MlUyQDN2IN88US=>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TE-12	NF7IfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NV7sfWo1UUN3ME24MlU6QTNzIN88US=>	NHL5XWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
YH-13	NUfNUJAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mo[5TWM2OD16Lk[xNFA5KM7:TR?=	M4ewelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SF126	NUS5UG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmXMTWM2OD16LkizPFY2KM7:TR?=	MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
J82	NIToUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHTZZ5FKSzVyPUiuPVAxOzhizszN	M2r1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RCC10RGB	NHzte3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{PUbGlEPTB;OD65PVU3OSEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-UT-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3fnW2lEPTB;OT6wOFk1PSEQvF2=	M3O5e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
LB2241-RCC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYjYemhpUUN3ME25MlE6OTN5IN88US=>	NV70TWV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
LB996-RCC	MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYi3VohiUUN3ME25MlE6QDlizszN	MkL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EPLC-272H	M2Xqdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEPPV\|BKSzVyPUmuN\|c3PTdizszN	NEfCV4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CTV-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYnmbWluUUN3ME25MlU3PTN{IN88US=>	NGixNI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HSC-2	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlXXTWM2OD17LkW3OVUh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-28	NHS0O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXjI[3IxUUN3ME25MlYyQDl\|IN88US=>	NIHLeW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MMAC-SF	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkfxTWM2OD17Lk[4O\|Uh\|ryP	NVTIdlNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CP50-MEL-B	NVnhSodjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{f6[GlEPTB;OT63OVc5OiEQvF2=	M3jpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HT-1080	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlHaTWM2OD17Lke3O\|M6KM7:TR?=	M4XiOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HEC-1	NFzVOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml3CTWM2OD1zMD6zN\|UzKM7:TR?=	M1zL[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
AGS	NHixUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX\JR\|UxRTFyLkO3OEDPxE1?	NHzp[HA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
GAMG	NYezXW9wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV;JR\|UxRTFyLkWxOlIh\|ryP	NFjKZpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SW48	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHTYNGNKSzVyPUGwMlUyQDlizszN	M{X4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
U031	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFu3T5RKSzVyPUGwMlU6ODhizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OVCAR-5	NFLSdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3vafWlEPTB;MUCuOlQzQSEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SF295	NWDBPGpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NInrT2FKSzVyPUGwMlY4ODRizszN	MmLXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
BHT-101	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYPJR\|UxRTFyLkexO\|ch\|ryP	NHXXSWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
VMRC-RCZ	NIDuRVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnrRTWM2OD1zMT6zNlAyKM7:TR?=	MnvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ACHN	MmfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXXJR\|UxRTFzLkSyNVEh\|ryP	M3Hxb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H526	NYnqdHhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3HzeGlEPTB;MUGuOVA1OyEQvF2=	M2LOUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MN-60	M4Huc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGe2bI9KSzVyPUGxMlU{QSEQvF2=	MnmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H2291	M1:ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXfJR\|UxRTFzLkW0OlYh\|ryP	M2TlSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SCC-25	M1vqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MofCTWM2OD1zMT63OVU3KM7:TR?=	M3XqOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-MEL-2	NIrNNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4jJWWlEPTB;MUGuO\|Y{PyEQvF2=	MlHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SN12C	M{e5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LLNGlEPTB;MUGuPVM2PSEQvF2=	Ml3pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H69	NYrH[oNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYDJR\|UxRTF{LkSyN\|Qh\|ryP	NX3QbWRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ME-180	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NV3rfXdlUUN3ME2xNk44ODV2IN88US=>	MlzHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MC-IXC	M1jPOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmruTWM2OD1zMj63OVE5KM7:TR?=	M2LvRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2347	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFPnZnZKSzVyPUGyMlc3OTRizszN	NYXnW2RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
M059J	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUizWVY4UUN3ME2xNk44PzJ5IN88US=>	MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
A2058	NYO4TmgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1vTRWlEPTB;MUKuPFY5OSEQvF2=	NFXNUmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
VA-ES-BJ	NXTvUGF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mne2TWM2OD1zMj64O\|g2KM7:TR?=	NHnuVZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
Ca9-22	NHzyR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIrLSGFKSzVyPUGyMlk1PTFizszN	M2TIeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KNS-42	NVz5c2NMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmK0TWM2OD1zMj65PVg1KM7:TR?=	MlXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LoVo	NVvPTndWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlPlTWM2OD1zMz6yN\|E{KM7:TR?=	M3m0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
AM-38	M4[2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NE\0WZRKSzVyPUGzMlI2PjZizszN	NUTuOId2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVrS[lFoUUN3ME2xN{4{PzV{IN88US=>	Ml3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
L-363	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGXGXGZKSzVyPUGzMlQxOzNizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-30	M4XPPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWrJR\|UxRTF2LkC2OFUh\|ryP	MlLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1563	Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlLpTWM2OD1zND62NFM6KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2228	NF;DbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX:1O2Y6UUN3ME2xOE43ODd5IN88US=>	MnPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MFM-223	NX7qemZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3\YbWlEPTB;MUWuNVgyOyEQvF2=	MoHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LB831-BLC	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NY\VU4tHUUN3ME2xOU4zPzZ5IN88US=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW872	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnrPYV2UUN3ME2xOU4{ODh4IN88US=>	Mm\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H522	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlT1TWM2OD1zNT6zN\|A3KM7:TR?=	NELiW4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
EW-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWDrR4JQUUN3ME2xOU42PDZ{IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HN	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnLVTWM2OD1zNT61PVQzKM7:TR?=	M1\XOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW837	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXHJR\|UxRTF3Lke4OFch\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SCC-9	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYDSUIVWUUN3ME2xOU45OTF2IN88US=>	NH65fVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
MKN7	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUTkVWE3UUN3ME2xOU46PzN{IN88US=>	M1jMdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KYSE-410	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH\UXHdKSzVyPUG2MlU6OSEQvF2=	M3G2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-N-DZ	NXu2OoxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2TmSWlEPTB;MU[uOlEyPiEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
COR-L105	NHnUcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWfJR\|UxRTF4Lk[1Nlgh\|ryP	MoTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
LB2518-MEL	M4rOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1\xd2lEPTB;MU[uPFM5QSEQvF2=	MnHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OVCAR-4	NV3L[442T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MULJR\|UxRTF4Lki4OlIh\|ryP	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TK10	NVu1bYNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlL0TWM2OD1zNj65OFc{KM7:TR?=	M3;rR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KNS-62	NV20T5pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWXJR\|UxRTF4Lkm3O\|ch\|ryP	NW\aWYdORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
RPMI-8866	NXf0OJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVTJR\|UxRTF5LkG3N\|Ih\|ryP	M1\5ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HuP-T4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{PDVWlEPTB;MUeuNlQ6PSEQvF2=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
CGTH-W-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmfzTWM2OD1zNz61NlE6KM7:TR?=	M3\WWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
T-24	NVPFR\|hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWXJR\|UxRTF5LkWzOFch\|ryP	M1vERlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HT-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2nCcGlEPTB;MUeuOVkyPCEQvF2=	NVjJZXBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
KS-1	NXT3ZmlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY\JR\|UxRTF5Lk[3N{DPxE1?	M4Dh[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1792	NFzsW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkPFTWM2OD1zNz63PVgh\|ryP	NWLWTFF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
ABC-1	MkXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mm\xTWM2OD1zNz64NVQyKM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
BPH-1	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3jKUWlEPTB;MUiuNVY5PSEQvF2=	NXHLWXJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
A431	M{Swcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWThSZhVUUN3ME2xPE41OTJ5IN88US=>	NIfHWI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
T98G	NGD6S25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEDncVJKSzVyPUG4MlUyPTdizszN	NW\zNXlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
BHY	M{TBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVLjRZB3UUN3ME2xPE45PjlizszN	MmLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
Capan-2	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MULJR\|UxRTF6LkmwO\|gh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
MDA-MB-175-VII	NVrVVGY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXKxc5BlUUN3ME2xPE46OjB7IN88US=>	NXLkOFlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CAL-27	Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoK0TWM2OD1zOT6wOFg4KM7:TR?=	M1zwNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
AsPC-1	Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEPyUZZKSzVyPUG5Mlg3PTdizszN	M4\2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
KU812	NH\LdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWPYeIV[UUN3ME2xPU46PTd\|IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H441	M2no[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlXUTWM2OD1{MD6wNFEh\|ryP	M3\vblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Mewo	MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV7lSG9NUUN3ME2yNE4yOjh6IN88US=>	NEXERZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SK-MEL-24	NVXMOpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Moe4TWM2OD1{MD6xOFc4KM7:TR?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H727	NHzQSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3XQOWlEPTB;MkCuNlcxPCEQvF2=	Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EKVX	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYrJR\|UxRTJyLk[wOkDPxE1?	M1PpeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
RT-112	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYrJR\|UxRTJyLk[xNlIh\|ryP	NEP0dnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
CAMA-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWjJR\|UxRTJyLkm4NFMh\|ryP	MnfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW900	M4rYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NITwTmFKSzVyPUKxMlAyPDlizszN	NHrlVXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H23	M3nJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUjK[HZ{UUN3ME2yNU4yOjd5IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SK-PN-DW	NV3NWI4yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnTsTWM2OD1{MT6xOlQ6KM7:TR?=	NInNT4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
BB30-HNC	NXXXNnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTJzLkK3OFUh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
VM-CUB-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4nHW2lEPTB;MkGuN\|U{PiEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
IST-MEL1	NG\ZcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2Hkb2lEPTB;MkGuN\|Y6OiEQvF2=	NVfOOFIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CTB-1	NGXDdZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1rQOWlEPTB;MkGuOFc2PSEQvF2=	NGTjN\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
LCLC-103H	M1;QUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFXl[YxKSzVyPUKyMlE2QDJizszN	M33ReFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
PANC-03-27	M1nHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUf5bWNvUUN3ME2yNk42OTZ7IN88US=>	NEfkO\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HTC-C3	M4Lz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUHke\|RGUUN3ME2yNk42PTV3IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TE-8	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFLs[21KSzVyPUKzMlI2PjVizszN	M1L3SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H292	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIDoOFdKSzVyPUK1MlM2OzZizszN	MnnnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
COLO-680N	M4WwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXPWbXl{UUN3ME2yOU43OzJ7IN88US=>	NInrVYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
KYSE-520	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWTJR\|UxRTJ3Lk[0OEDPxE1?	NXnYRlNPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
NB10	M2HNb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGDFVZpKSzVyPUK2MlMyOTdizszN	Mmq2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H661	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MmrBTWM2OD1{Nj60O\|E{KM7:TR?=	NVTvenB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
GMS-10	MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVzJR\|UxRTJ4Lki2N\|gh\|ryP	M4jKfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2122	NXLJO3ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYXJR\|UxRTJ4Lkm5PVgh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
OVCAR-8	NX\kNoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY\JR\|UxRTJ5LkC2N\|gh\|ryP	Ml7NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
DJM-1	Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGjWUZJKSzVyPUK3MlE1PTRizszN	M{npZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
UACC-893	NVXuZ3RJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYPJR\|UxRTJ5Lkm4O\|gh\|ryP	M2HMSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
C8166	M2nYPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIHhbnNKSzVyPUK4MlY6OzhizszN	M1vyb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H1693	M1fYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXO3d4J2UUN3ME2yPE43QTd3IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
TYK-nu	NXPRU2hkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NES0NZVKSzVyPUOwMlA{PDVizszN	MkTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SW1710	NYfMbVc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYPJR\|UxRTNyLkGyOkDPxE1?	NXr4PY92RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
A375	MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn72TWM2OD1\|MD6zNlQ{KM7:TR?=	M17oUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HMV-II	MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXHJR\|UxRTNzLkO1PVIh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
NCI-H2087	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkjHTWM2OD1\|MT62N\|UzKM7:TR?=	MmK1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
CAL-54	MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUTMZppsUUN3ME2zNU44OjRzIN88US=>	MkXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
HCC70	NFLnWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17UNWlEPTB;M{KuNVM5PyEQvF2=	MmDNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
ES1	M3iwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXrrUlQ4UUN3ME2zNk4{ODZ{IN88US=>	MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H1355	M1jvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV3JR\|UxRTN\|LkKwOEDPxE1?	NVT6WnVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CFPAC-1	NF;qVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUfGeFdbUUN3ME2zN{4zOzN{IN88US=>	MkXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
MKN28	MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3\FPGlEPTB;M{OuN\|gxQSEQvF2=	NFzDTJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HDLM-2	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1fBRWlEPTB;M{OuOlk{OSEQvF2=	MlXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
PANC-10-05	NE\OXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUnJR\|UxRTN2LkGwNVQh\|ryP	NGPUUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SAS	M2q3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUDHbHFqUUN3ME2zOE41PTZ3IN88US=>	M1\keFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
HCC1395	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX;0W2c{UUN3ME2zOE44OTh4IN88US=>	NHzmUok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
8305C	NYrReWMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUSycFM{UUN3ME2zOU45PDF3IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
KM12	M4nCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYLReVBKUUN3ME2zOk44PTR5IN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1116	NUTmVnkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{npR2lEPTB;M{euOVk6OiEQvF2=	MlH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3\UbmlEPTB;M{iuN\|M5QSEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HCC2218	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3PhN2lEPTB;M{iuOlUyQSEQvF2=	NHnMPYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
T84	NEOx[YJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MX\JR\|UxRTN6Lke0NFkh\|ryP	NED6eHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ETK-1	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHzkXGZKSzVyPUO5MlAzOiEQvF2=	M2fodVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
COLO-800	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUfzPVFqUUN3ME2zPU4{QDZ6IN88US=>	NULyO\|MyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
CAL-12T	MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnvlTWM2OD1\|OT61NlgyKM7:TR?=	NFHKelY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
ACN	M4DBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVKySJloUUN3ME20NE41QTFzIN88US=>	NIj5[2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
SJSA-1	NUDmOWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3PHVmlEPTB;NEGuNVU6PiEQvF2=	NGnrPFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
PSN1	MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVP0d5NCUUN3ME20NU4yPzR7IN88US=>	NH3LZ\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
D-566MG	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVHJR\|UxRTRzLkKwPFYh\|ryP	MlzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
EGI-1	NXrxNI06T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX3JR\|UxRTR{LkSyPEDPxE1?	NFTOSZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
A204	NGXwWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEXEW3dKSzVyPUSyMlY{QDhizszN	M4PTR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
Saos-2	NFP4TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH35cm1KSzVyPUSyMlg{PjlizszN	NV[zWoJKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPDR\|Nki0M{c,W0GQR1XSQE9iRg>?
SNU-C2B	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mnj0TWM2OD12Mz62PFc5KM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
HLE	NH7QXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NUPxTXlZUUN3ME20OE4xQDV4IN88US=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly0OFM3QDRxJ{7TRW5ITVJ:L3G+
SW1463	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXzJR\|UxRTR2Lkm5O\|Eh\|ryP	NFK2VlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
DSH1	NGPWXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX:4NmN4UUN3ME20OU4xODN\|IN88US=>	M{nZclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
MCF7	NVfqZXR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFHsS3pKSzVyPUS1MlUxPTFizszN	Mlj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
K5	M3;6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWLJR\|UxRTR3Lkm0NFUh\|ryP	MlHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
NCI-H358	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{jCVGlEPTB;NEeuNlE2KM7:TR?=	NFvMdVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
NCI-H2030	MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUPJR\|UxRTR5LkKzO\|Qh\|ryP	M1LVTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SW948	M3fmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkTzTWM2OD12Nz60OlQh\|ryP	M4exRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
BALL-1	M3Swcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYjzfpZoUUN3ME20O{43OTZ6IN88US=>	NH\vXII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
TE-9	NFT1Z4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYrJR\|UxRTR5Lkm1PFEh\|ryP	M{jBPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
SK-N-FI	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4D3XGlEPTB;NEiuNFM2QCEQvF2=	Ml3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
KALS-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NELPVZVKSzVyPUS4MlEzQDlizszN	NHrTS3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw1PDN4OESvK\|5USU6JRWK8M4E,
HO-1-N-1	M{Tvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mn;LTWM2OD12OD63OFQ2KM7:TR?=	M4njWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>
NCI-H2452	NYHQUW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFjxUJNKSzVyPUS5MlEyPTJizszN	MknvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOFQ{Pjh2Lze+V2FPT0WUPD;hQi=>
OC-314	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV;SVmJLUUN3ME20PU43QDN2IN88US=>	M4DtdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFQ1OzZ6ND:nQnNCVkeHUkyvZV4>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

体内研究

用ABT-263处理H345移植瘤模型，按动物体重，每千克每天处理10mg ABT-263，结果肿瘤生长抑制率达80% ，肿瘤体积减小了50%以上，显示出ABT-263极强的抗癌效果。ABT-263作用于非小细胞肺癌和急性淋巴细胞白血病的移植瘤模型时，每天单独口服，结果显示肿瘤完全衰退。ABT-263单独作用于B-细胞淋巴瘤和多发性骨髓瘤的移植瘤模型时效果不明显，但是可以显著增强临床其他相关用药的药性。^[2]

激酶实验： ^[1]	- 合并激酶实验: 用竞争性荧光偏振检测测定ABT-263 作用于Bcl-2 家族不同亚型的Ki值或者IC50值。使用如下的肽探针对或者蛋白对：f-bad (1 nM) 和Bcl-xL (6 nM), f-Bax (1 nM) 和Bcl-2 (10 nM), f-Bax (1 nM) 和Bcl-w (40 nM), f-Noxa (2 nM)和Mcl-1 (40 nM), 及f-Bax (1 nM) 和Bcl-2-A1 (15 nM)。用时间分辨荧光共振能转移法测定ABT-263和Bcl-xL作用的结合紧密度。1 nM 用His标记的Bcl-xL 与200 nM f-Bak,及 1 nM Tb标记的His抗体混合, 然后在室温下处理30分钟。
细胞实验： ^[1]	- 合并 Cell lines: SCLC 细胞系 Concentrations: 0-1 μM Incubation Time: 48小时 Method: 人类肿瘤细胞系在37^oC 含5% CO₂环境下获得，SCLC 细胞系培养在RPMI 1640培养基中，培养基包含10% 胎牛血清, 1% 丙酮酸钠, 25 mM HEPES, 4.5 g/L葡萄糖, 1% 青霉素/链霉素。用含有10% FBS和1% 青霉素/链霉素的RPMI 1640培养基培养白血病和淋巴癌细胞系。细胞在96孔板上处理48小时，最终体积达到100ul。在体外测试ABT-263的细胞毒性。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: C.B.-17严重联合免疫缺陷-米黄鼠 Dosages: 100 mg/kg/d Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	4mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Navitoclax (ABT-263) SDF

分子量	974.61
化学式	C₄₇H₅₅ClF₃N₅O₆S₃
CAS号	923564-51-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04480086	Active not recruiting	Drug: Mivebresib\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	March 17 2021	Phase 1
NCT04454658	Recruiting	Drug: ABBV-744\|Drug: Navitoclax\|Drug: Ruxolitinib	Myelofibrosis (MF)	AbbVie	August 19 2020	Phase 1
NCT04041050	Recruiting	Drug: Navitoclax\|Drug: Ruxolitinib\|Drug: Celecoxib	Myeloproliferative Neoplasm	AbbVie	November 8 2019	Phase 1
NCT03181126	Completed	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Active not recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
回答：
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
问题 2：
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
回答：
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

选择性强的Bcl-2抑制剂

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
用于临床的Bcl-2抑制剂

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
经典的Bcl-2抑制剂

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

研究领域

产品类型

定制您的化合物库

Navitoclax (ABT-263)

客户使用Selleck生产的Navitoclax (ABT-263)发表文献252篇：

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Navitoclax (ABT-263) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-05-17)

技术支持

常见问题及建议解决方法

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品